Top domestic and imported automakers Hyundai Motor and Mercedes-Benz may give way to other competitors in sales performance in South Korea this year.
According to industry tracker CarIsYou Data Research Center, Kia Corp. registered 37,371 new vehicles last month, surpassing Hyundai's 35,993 units, including those from the Genesis brand, to become the top domestic carmaker for the first time.
While Kia trails Hyundai in terms of total registered vehicles between January and August, its strong performance, including the Sorento SUV topping sales charts last month, is still noteworthy in the auto industry.
Last month, BMW registered 7,305 units in the imported vehicle market, surpassing Mercedes-Benz's 5,943 units to top the sales charts.
As of last month, Mercedes-Benz had 50,627 registered vehicles and BMW had 50,349 registered vehicles, indicating that the sales gap between the two automakers is narrowing.


Oil Prices Crash 15% as Trump and Iran Agree to Two-Week Ceasefire
U.S. Futures Slip as Iran Ceasefire Uncertainty and CPI Data Weigh on Markets
Oil Prices Crash Nearly 15% After Trump-Iran Ceasefire Deal
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Trump Suspends Iran Strikes for Two Weeks as Ceasefire Talks Begin
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Japan Consumer Confidence Drops Sharply Amid Rising Fuel Costs and Middle East Tensions
Britain Courts Anthropic Amid US Defense Department Dispute
U.S.-Iran Ceasefire: Fragile Truce Raises Hopes for Strait of Hormuz Peace Deal
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Asian Markets Retreat as Gulf Crisis Fuels Oil Surge and Inflation Fears
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
China Set to Exit Deflation Cycle in Early 2026, ANZ Analysts Say
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



